Michael Blaha
Cardiovascular Disease · Baltimore, MDNPI 1285770313
Payments from drug & device makers
Across 328 payments — averaging $2594.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$417K
- Bayer Healthcare LLC$176K
- Bayer$61K
- Amgen$52K
- Siemens Medical Solutions USA, Inc.$19K
- Par Pharmaceutical, Inc.$18K
- plus $108K from 17 others
Across 1 payment — averaging $7020.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bayer$7K
What the payments were for
- Consulting fees$429,95471%
- Speaking & faculty fees$129,90921%
- Travel & lodging$41,6397%
- Food & beverage$7,5901%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 169 | $416,825 |
| Bayer Healthcare LLC | 39 | $176,140 |
| Bayer | 4 | $60,832 |
| Amgen | 28 | $52,272 |
| Siemens Medical Solutions USA, Inc. | 17 | $19,125 |
| Par Pharmaceutical, Inc. | 1 | $17,550 |
| Lexicon Pharmaceuticals, Inc. | 4 | $14,597 |
| Alnylam Pharmaceuticals Inc. | 1 | $13,395 |
| Merck | 18 | $12,336 |
| Novartis | 10 | $10,812 |
| Gilead | 1 | $10,500 |
| Boehringer Ingelheim | 6 | $10,461 |
| Sanofi US Services Inc. | 9 | $10,250 |
| Idorsia Pharmaceuticals US Inc | 4 | $7,404 |
| Genentech, Inc. | 3 | $6,193 |
| Roche Diagnostics International Ltd | 2 | $5,600 |
| Lilly USA, LLC | 2 | $3,200 |
| AstraZeneca | 1 | $2,954 |
| Novo Nordisk AS | 2 | $249 |
| GE HealthCare | 1 | $112 |
| Regeneron Healthcare Solutions, Inc. | 2 | $100 |
| Sanofi-aventis U.S. LLC | 3 | $47 |
| Pfizer | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$850,968 in reported general payments places this provider in the 95th percentile of 507 cardiovascular disease providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 34 | $55,473 |
| OzempicSemaglutide | 45 | $48,371 |
| JardianceEmpagliflozin | 26 | $35,318 |
| MounjaroTirzepatide | 31 | $32,121 |
| EliquisApixaban | 21 | $18,264 |
| Ezetimibe | 55 | $2,830 |
| Rosuvastatin Calcium | 60 | $1,862 |
| Atorvastatin Calcium | 91 | $1,647 |
| Metoprolol Succinate | 42 | $624 |
| Carvedilol | 25 | $557 |
| Losartan Potassium | 39 | $542 |
| Nifedipine ErNifedipine | 11 | $302 |
| Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide | 11 | $178 |
| Amlodipine Besylate | 13 | $150 |
| Furosemide | 23 | $121 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $416,825 | $48,37145 claims |
| Boehringer IngelheimJardiance | $10,461 | $35,31826 claims |
| Lilly USA, LLCMounjaro | $3,200 | $32,12131 claims |
| PfizerEliquis | $13 | $18,26421 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 507 cardiovascular disease providers in Maryland.
Other cardiovascular disease in Baltimore
- Christopher DefilippiBaltimore$9.2M
- Thorsten LeuckerBaltimore$7.1M
- Joao LimaBaltimore$5.6M
- Jeffrey ColeBaltimore$4.8M
- Carlos InceBaltimore$3M
- Paul GurbelBaltimore$2.6M
- Navin KapurBaltimore$1.8M
- Robert WeissBaltimore$1.4M
- Stephen GottliebBaltimore$1.4M
- Jesse DoranBaltimore$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.